ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs. The Company’s lead investigational compound, ATX-01, is advancing into clinical development for the treatment of myotonic dystrophy type 1 (DM1), a devastating, rare neuromuscular disorder that causes muscle weakness and other life-limiting complications which affects at least 40,000 people in the U.S and 70,000 in Europe.
Sound Contact: Bibhash Mukhopadhyay (Board Director) and Ester Sklarsky (Board Observer)
Read an interview with CEO Dr. Frédéric Legros Reaching the next level of creating novel therapies for genetic diseases
